TP53 and endometrial cancer: In addition, p53 mutation was independently associated with prolonged PFS, suggesting it may be a biomarker of response.<h4>Key messages</h4>What is already known on this topic:Pembrolizumab plus lenvatinib has been an emerging treatment for recurrent endometrial cancer, showing survival benefit in pMMR tumors.